多替阿巴拉米片多少钱？

Five months after receiving formal approval from the State Food and Drug Administration (CFDA), the British pharmaceutical company GlaxoSmithKline (GSK) recently announced that its joint venture ViiV Healthcare’s new anti-AIDS drug Suimeikai (chemical name:) has been officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. As global anti-AIDS drug research and development accelerates, AIDS treatment trends are changing. Traditional combination drug treatment regimens have problems such as strong drug interactions, serious side effects, and poor patient compliance. Compound drugs have become a new direction in the research and development of anti-AIDS drugs.

In 2014, GSK's three-in-one anti-AIDS drug Triumeq (i.e., dolutea palamid tablets) was approved for marketing in the United States. Subsequently, the four-in-one new anti-AIDS drug Genvoya and the three-in-one new drug Odefsey developed by Gilead were also released one after another. In the Chinese mainland market, the launch of dolutea palamid tablets has filled the gap in single-pill compound preparations of anti-AIDS drugs. Dolutegravir tablets are the only three-in-one compound drug with dolutegravir (DTG) as the core. Patients only need to take one tablet each time.

This is the second anti-AIDS drug launched by GSK in mainland China within two years. In June 2016, the new generation of integrase inhibitor Tevicai (chemical name: dolutegravir) developed by GSK was officially launched in China. This drug is the only first-line option for integrase inhibitors included in the World Health Organization HIV antiviral guidelines. At present, foreign pharmaceutical companies still dominate the domestic anti-AIDS drug market. In addition to GSK, Merck, Roche, Johnson & Johnson, etc. all have anti-AIDS drugs on the market in the country. Among domestic companies, Aibovitai, a national first-class new drug independently developed by Nanjing Frontier Biotech, has completed Phase III clinical trials, and ACC007, developed by Jiangsu Aidi Pharmaceutical, received CFDA clinical approval in 2017.

Previously, GSK's Tevicai and Merck's Ascent (raltegravir potassium tablets) were priced at 1,980$/box, while the newly launched Dolutegravir tablets were priced at 2,880$/box, which is a long-term cost for patients who need to take this drug for a long time. Inbec, a box of 30 tablets produced by the Indian company Emcure, sells for about RMB 1,000, making it the most cost-effective tablet on the market.